Abiomed

Impulse Dynamics is a medical device company offering innovative solutions for the treatment of chronic heart failure. Its CCM® therapy is specifically designed to improve the contraction of the heart to deliver more oxygen-rich blood to the body. The therapy is a safe and effective minimally invasive treatment option for millions of heart failure patients who otherwise have few or no effective options available to them.

preCARDIA is a provider of inpatient partially implantable devices for treating patients with acute decompensated heart failure.

Breethe, Inc. is a medical device company that focuses on developing wearable artificial lungs for both hospital and home use. Its flagship product, the OXY-1 System, is a portable external respiratory assistance device designed to facilitate blood circulation and gas exchange for patients experiencing acute respiratory or cardiopulmonary failure. This innovative technology allows for the removal of carbon dioxide and the addition of oxygen to the bloodstream, mimicking the function of a healthy lung. By eliminating the need for cumbersome oxygen tanks, the OXY-1 System enables patients requiring ECMO therapy to maintain greater mobility. Founded in 2014 and headquartered in Halethorpe, Maryland, Breethe operates as a subsidiary of Abiomed.

Impulse Dynamics is a medical device company offering innovative solutions for the treatment of chronic heart failure. Its CCM® therapy is specifically designed to improve the contraction of the heart to deliver more oxygen-rich blood to the body. The therapy is a safe and effective minimally invasive treatment option for millions of heart failure patients who otherwise have few or no effective options available to them.

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

ProtEmbo is designed to be a simple and reliable solution for one of the most feared complications during TAVR. The advent of transcatheter treatments for valvular heart disease has been a major revolution in the care of patients with disabilities or intercurrent illnesses that precluded undergoing stressful open cardiac surgical procedures. Nonetheless, in spite of ongoing improvements in TAVR procedures and outcomes, the occurrence of cerebrovascular events represents a significant morbidity of TAVR. Protembis was founded based on the vision to reduce the risk of cerebrovascular events, thereby improving outcomes and making TAVR even safer – especially in light of TAVR shifting to younger and lower-risk patients. The ProtEmbo System is an adjunctive device used during TAVR and removed following completion of valve implantation. The ProtEmbo is an intra-aortic filter device that is designed to deflect embolic material arising during TAVR away from the cerebral circulation.

Our newest product, RenalGuard®, has been developed to help prevent the onset of contrast-induced nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. It is already approved for sale in the EU for general fluid balancing. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by the FDA.

Reprieve Cardiovascular is a pioneering medical device company focused on innovative fluid management technologies for congestive heart failure. The company's Reprieve technology is being investigated as an innovative fluid management treatment. Providing clinicians with the ability to precisely control a patient’s fluid volume may both enable improved cardiac care, as well as, be instrumental in the decongestion of acutely decompensated heart failure patients (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are subsidiaries of parent company CardioRenal Systems, Inc.

Founded in October, 2012, Magenta Medical Ltd. is a privately held company that is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.

ALung Technologies is a medical device manufacturing company that develops intracorporeal and extracorporeal gas exchange devices for the treatment of acute and chronic respiratory disorders. Its technology utilizes Hemolung, an extracorporeal gas exchange device that circulates blood through a small catheter; and Hattler Catheter, which is placed within the central venous bloodstream in the primary vein that returns blood to the heart and is inserted directly through the skin into the vein. The company was founded in 1997 and headquartered in Pittsburgh, Pennsylvania.

ECP Entwicklungsgesellschaft is a a medical device company and is developing a product that is a percutaneous, expandable catheter pump which increases blood circulation from the heart with an external drive shaft.

Impella CardioSystems AG, based in Aachen, Germany, develops, manufactures and markets minimally invasive cardiovascular support systems for numerous indications in the fields of cardiology and coronary surgery. The company's technology is protected by more than 30 European and international patents, and currently employees 50 individuals. For the last 2 years Impella has been affiliated with and assisted by Accelerated Technologies, Inc (ATI), a medical device accelerator located in Hackensack, NJ.